Hodgkin's Lymphoma -evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio -Fortaleza, Brazil. 3 , Beatriz stela Gomes de souza PitomBeira arauJo 3 , clara maria Bastos eloy da costa 4 , acy teles quixadá-medica 5 , Jacqueline de souza holanda 5 , samuel Vasconcelos landim 6 , maria helena PitomBeira Hematology Service, where they are seen in the PreTransplantation Outpatient Clinic for reassessment of BMT indication. Patients are referred with their respective medical records from the original service, containing the biopsy diagnosis report, immunohistochemistry, chemotherapy and radiotherapy protocols performed, date of recurrence or whether the patient is refractory to treatment. With these first recommendations the patient is enrolled in the BMT waiting listing, after which medical history and complete physical examination, hematological, biochemical and imaging evaluations are performed. A dental assessment, consultations with a nutritionist and psychologist are also requested.
The results are then analyzed for the patient to be referred to the transplantation team to schedule the mobilization and collection of hematopoietic stem cells and subsequent hospitalization for cell conditioning and infusion. Regarding the first treatment, all patients received the ABVD polydrug regimen (Adriamycin, bleomycin, vinblastine, dacarbazine), of which 16 underwent associated field radiotherapy. In response, 21 patients went into complete remission, 16 into partial remission and 15 did not respond. Of the 21 in CR, recurrence ranged from 5 months to 14 years, whereas two had HL recurrence after less than 6 months, seven between 6 and 12 months and twelve more than 12 months (Chart 2).
As the second treatment due to recurrence or no response/refractory patient, 35 (62.5%) patients received the ICE regimen 12 (20.8%) ICE associated to another polychemotherapy regimen, five received DHAP, two received ESHAP and one received ABVD. The analysis of the response at this step of treatment showed that 27 (51.9%) achieved CR, whereas 25 (48.1%) had PR.
All patients received GCS-F during mobilization, and 35 were mobilized only with G-CSF, 15 with Vinorelbine and G-CSF, two with Plerixafor and G-CSF. CD34 collection ranged from 2.03 to 18.39 X10 6 CD34 cells/kilogram, with a mean of 4.8. The waiting time until transplantation ranged from 26 to 274 days, with a mean of 86.3 days.
Conditioning was performed with BEAC in 34 (65.4%), NEAM in 13 (25.0%) and BEAM in five (9.6%) patients. Grafting varied from 7 to 15 days, occurring in 19 (36.6%) patients in less than 10 days, in 28 (50%) between 10 and 12 days, in 3 (5.7%) more than 12 days and 2 (3.8%) showed no grafting.
The post-BMT results up to D+100 showed: CR -42 (82.7%), PR -8 (13.5%) and 2 (3.8%) deaths, which occurred 3 and 6 days after cell infusion. After D+100, 8 patients in CR showed HL recurrence between 6 and 36 months; 3 died and 5 are being treated with brentuximab; of the 8 patients in PR, 1 died due to HL activity four months after the BMT and 7 are undergoing treatment (2 with allogeneic transplant indication).
Charts 3 and 4 show the results considering patient clinical status (CR and PR) before BMT, the assessment on D+100 and the last report (May 2016 Seven years after the first and seven months after the last evaluated BMT (October 2015), the following results were observed: CR -32 (61.6%) patients, PR and treatment -14 (26.9%) and 6 (11.5%) deaths. The overall survival, disease-free curves and chemosensitive and chemoresistant cases are shown in graphs 1, 2, 3 and 4.
discussion
The Hematological Service of HUWC/UFC/ HEMOCE has 50 years of experience with HL and 1045 followed cases. Eight years ago, a Bone Marrow Transplant Unit was implemented, a procedure that brought a new dimension to patients with refractory disease.
The prognosis of Hodgkin's lymphoma has improved considerably with the new chemotherapy regimens and advancements in radiotherapy techniques, allowing young patients to have a disease-free survival rate of approximately 80% and even achieving the cure. 2, 3, 6 Currently, it is worth mentioning the new forms of treatment, including targeted therapy and the possibility of bone marrow trans- 
CHART 2. Distribution of patients according to the responses at several stages of transplantation
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Time plant indication not only in young patients, but also in those at older age groups. 7, 8, 9, 10, 11, 12 The present analysis of transplanted patients at UTMO/HUWC/UFC shows a young population (mean age of 28 years), with a predominance of localized disease (I+II), mostly B, initially treated with standard regimen (ABVD) and who did not respond or had recurrence, becoming candidates for a new treatment regimen and the possibility of BMT indication. However, 50.0% of them came to transplantation in partial remission of the lymphoma, showing much lower results when considering the patient coming to the BMT in complete remission (64.7% vs. 35.3%). These data show the importance of trying to perform the transplant with the patient in the best possible The conditioning with the BEAC regimen showed to be very effective, as well as the NEAM (91.1% vs. 84.6%) regarding the achievement of CR in patients evaluated at the level of D+100. Some conditioning regimens suggest adding bortezomib to other drugs, but there was no significant difference in the outcome. 14 The final evaluation of the transplanted HL patients showed an overall survival rate of 88.5% and 61.5% disease-free survival at six years, with an overall survival of chemosensitive patients of 81% and 72.6% in chemoresistant ones, results comparable to other transplant centers 15, 16 
